Diagnostics and Therapeutics for HIV: Global Markets
The global market for HIV therapeutics is expected to grow to $18.2 billion in 2013 and $19.6 in 2018, with a compound annual growth rate (CAGR) of 1.5%.
- An overview of the global market for HIV therapeutics and diagnostics
- Analyses of global market trends, with data from 2013, and estimates and projections of CAGRs through 2018.
- Discussion of improvements in advanced treatments and diagnostic methods.
- Examination of cost implications for treatments accross a wide range of countries
- A look at ongoing research and the future direction of the market.
SCOPE AND FORMAT
This report summarizes the market of HIV/AIDS products and discusses the present status and evolution of antiretroviral (ARV) drugs with analyses by selected major national markets. The latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed. The current market for antiretroviral therapies is analyzed, with breakdowns by drug categories, and the leading drugs of 2012 are discussed. Five-year forecasts are provided with reasonable explanations. This report also summarizes the research efforts in early HIV prophylaxis, including pre-exposure prophylaxis, post-exposure prophylaxis and prevention of HIV transmission from mother to infant. Finally, major research efforts for developing HIV vaccines are summarized and promising directions are identified.
Kritika Chaudhari is an independent research analyst and has written extensively about a wide range of therapeutic areas. She has worked in laboratory research settings in the United States and the United Kingdom, and now provides market analysis and intellectual property due-diligence services as a freelance consultant, specializing in early-stage and emerging research in the biotechnology and pharmaceuticals industries.
The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast period to reach $14.1 billion in 2016.